Maria Cristina Mingari

List of Publications by Year
in descending order

169	18,376	13865 67	12946 131
papers	citations	h-index	g-index

171	171	171	16745
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia. Cancer Immunology Research, 2022, 10, 291-302.	3.4	17
2	Characterization of <scp>KIR</scp> ⁺ <scp>NK</scp> cell subsets with a monoclonal antibody selectively recognizing <scp>KIR2DL1</scp> and blocking the specific interaction with <scp>HLAâ€€</scp>. Hla, 2022, , .	0.6	5
3	NK cells and ILCs in tumor immunotherapy. Molecular Aspects of Medicine, 2021, 80, 100870.	6.4	134
4	Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells. Journal of Allergy and Clinical Immunology, 2021, 147, 349-360.	2.9	65
5	Natural killer cell receptors regulate responses of HLA-Eâ€“restricted T cells. Science Immunology, 2021, 6, .	11.9	13
6	Human NK cells, their receptors and function. European Journal of Immunology, 2021, 51, 1566-1579.	2.9	75
7	Is there a role for tapered topical dose steroidal treatment for dry eye disease? A randomized, pilot study. European Journal of Ophthalmology, 2021, , 112067212110487.	1.3	2
8	EZH1/2 Inhibitors Favor ILC3 Development from Human HSPC-CD34+ Cells. Cancers, 2021, 13, 319.	3.7	9
9	Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity. Frontiers in Immunology, 2021, 12, 803014.	4.8	13
10	Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules. Blood Advances, 2020, 4, 2297-2307.	5.2	11
11	Phenotypic and Functional Characterization of NK Cells in Î±Î²T-Cell and B-Cell Depleted Haplo-HSCT to Cure Pediatric Patients with Acute Leukemia. Cancers, 2020, 12, 2187.	3.7	19
12	Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer. Frontiers in Immunology, 2020, 11, 2156.	4.8	49
13	TIGIT Blockade and IL15 in Tumor Immunotherapy: Together is Better. Clinical Cancer Research, 2020, 26, 5274-5275.	7.0	4
14	Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer. Frontiers in Immunology, 2020, 11, 125.	4.8	53
15	Targeted Therapies: Friends or Foes for Patientâ€™s NK Cell-Mediated Tumor Immune-Surveillance?. Cancers, 2020, 12, 774.	3.7	10
16	ILC3s: Rhythmic Keepers of Gut Integrity at Mealtime. Trends in Immunology, 2020, 41, 364-366.	6.8	0
17	Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation. Frontiers in Immunology, 2019, 10, 1179.	4.8	269
18	Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Cancers, 2019, 11, 125.	3.7	11

#	Article	IF	Citations
19	NKp44-NKp44 Ligand Interactions in the Regulation of Natural Killer Cells and Other Innate Lymphoid Cells in Humans. Frontiers in Immunology, 2019, 10, 719.	4.8	50
20	Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PDâ€1 receptor. International Journal of Cancer, 2019, 145, 1660-1668.	5.1	65
21	Heterogeneity of NK Cells and Other Innate Lymphoid Cells in Human and Murine Decidua. Frontiers in Immunology, 2019, 10, 170.	4.8	65
22	Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cellular and Molecular Immunology, 2019, 16, 430-441.	10.5	327
23	PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua. Mucosal Immunology, 2019, 12, 624-631.	6.0	45
24	Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board. Trends in Immunology, 2019, 40, 83-85.	6.8	37
25	Exploiting Human NK Cells in Tumor Therapy. Frontiers in Immunology, 2019, 10, 3013.	4.8	37
26	Human natural killer cells and other innate lymphoid cells in cancer: Friends or foes?. Immunology Letters, 2018, 201, 14-19.	2.5	50
27	Hypoxia Modifies the Transcriptome of Human NK Cells, Modulates Their Immunoregulatory Profile, and Influences NK Cell Subset Migration. Frontiers in Immunology, 2018, 9, 2358.	4.8	104
28	Molecular definition of group 1 innate lymphoid cells in the mouse uterus. Nature Communications, 2018, 9, 4492.	12.8	77
29	Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function. Frontiers in Immunology, 2018, 9, 2433.	4.8	15
30	Human Innate Lymphoid Cells: Their Functional and Cellular Interactions in Decidua. Frontiers in Immunology, 2018, 9, 1897.	4.8	62
31	PD-L1 Expression Heterogeneity in Nonâ€“Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. Journal of Thoracic Oncology, 2018, 13, 1113-1120.	1.1	135
32	NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines. Cancer Research, 2018, 78, 3913-3925.	0.9	53
33	PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263. Oncotarget, 2018, 9, 30465-30471.	1.8	26
34	Markers and function of human NK cells in normal and pathological conditions. Cytometry Part B - Clinical Cytometry, 2017, 92, 100-114.	1.5	110
35	A conserved energetic footprint underpins recognition of human leukocyte antigen-E by two distinct Î±Î² T cell receptors. Journal of Biological Chemistry, 2017, 292, 21149-21158.	3.4	20
36	PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. Oncotarget, 2017, 8, 90123-90131.	1.8	89

#	Article	IF	Citations
37	NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?. Journal of Immunology Research, 2016, 2016, 1-13.	2.2	65
38	NK Cells and Other Innate Lymphoid Cells in Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2016, 7, 188.	4.8	45
39	The generation of human innate lymphoid cells is influenced by the source of hematopoietic stem cells and by the use of Gâ€CSF. European Journal of Immunology, 2016, 46, 1271-1278.	2.9	38
40	Killer cell immunoglobulin-like receptor 3DL1 polymorphism defines distinct hierarchies of HLA class I recognition. Journal of Experimental Medicine, 2016, 213, 791-807.	8.5	81
41	Human NK cells: From surface receptors to clinical applications. Immunology Letters, 2016, 178, 15-19.	2.5	35
42	Human innate lymphoid cells. Immunology Letters, 2016, 179, 2-8.	2.5	52
43	Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias. Cancer Immunology, Immunotherapy, 2016, 65, 465-476.	4.2	34
44	Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function. Oncotarget, 2016, 7, 60858-60871.	1.8	14
45	ILâ€1Î² inhibits ILC3 while favoring NKâ€cell maturation of umbilical cord blood CD34⁺ precursors. European Journal of Immunology, 2015, 45, 2061-2071.	2.9	21
46	Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment. OncoImmunology, 2015, 4, e1052353.	4.6	34
47	MSC and innate immune cell interactions: A lesson from human decidua. Immunology Letters, 2015, 168, 170-174.	2.5	26
48	NCR+ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nature Communications, 2015, 6, 8280.	12.8	203
49	Role of NK cells in immunotherapy and virotherapy of solid tumors. Immunotherapy, 2015, 7, 861-882.	2.0	17
50	IL-1Â-releasing human acute myeloid leukemia blasts modulate natural killer cell differentiation from CD34+ precursors. Haematologica, 2015, 100, e42-e45.	3.5	14
51	Unique Eomes+ NK Cell Subsets Are Present in Uterus and Decidua During Early Pregnancy. Frontiers in Immunology, 2015, 6, 646.	4.8	107
52	A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation. Oncotarget, 2015, 6, 25602-25618.	1.8	79
53	Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts. Oncotarget, 2015, 6, 37426-37442.	1.8	21
54	Human NK Cells: From Surface Receptors to the Therapy of Leukemias and Solid Tumors. Frontiers in Immunology, 2014, 5, 87.	4.8	77

#	Article	IF	Citations
55	Human RORÎ³t+CD34+ Cells Are Lineage-Specified Progenitors of Group 3 RORÎ³t+ Innate Lymphoid Cells. Immunity, 2014, 41, 988-1000.	14.3	132
56	In vivo generation of decidual natural killer cells from resident hematopoietic progenitors. Haematologica, 2014, 99, 448-457.	3.5	43
57	Development of human natural killer cells and other innate lymphoid cells. Seminars in Immunology, 2014, 26, 107-113.	5.6	56
58	Effect of tumor cells and tumor microenvironment on NKâ€cell function. European Journal of Immunology, 2014, 44, 1582-1592.	2.9	313
59	Human Natural Killer Cells: Origin, Receptors, Function, and Clinical Applications. International Archives of Allergy and Immunology, 2014, 164, 253-264.	2.1	119
60	CD56brightPerforinlow Noncytotoxic Human NK Cells Are Abundant in Both Healthy and Neoplastic Solid Tissues and Recirculate to Secondary Lymphoid Organs via Afferent Lymph. Journal of Immunology, 2014, 192, 3805-3815.	0.8	197
61	Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages. Haematologica, 2014, 99, 1078-1087.	3.5	43
62	HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism. Haematologica, 2014, 99, 888-896.	3.5	43
63	Stromal Cells from Human Decidua Exert a Strong Inhibitory Effect on NK Cell Function and Dendritic Cell Differentiation. PLoS ONE, 2014, 9, e89006.	2.5	63
64	The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-Î± production. Journal of Translational Medicine, 2013, 11, 108.	4.4	136
65	Hypoxia downregulates the expression of activating receptors involved in <scp>NK</scp>â€cellâ€mediated target cell killing without affecting <scp>ADCC</scp>. European Journal of Immunology, 2013, 43, 2756-2764.	2.9	210
66	Natural killer cells in human pregnancy. Journal of Reproductive Immunology, 2013, 97, 14-19.	1.9	63
67	A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma. European Journal of Cancer, 2013, 49, 2022-2033.	2.8	44
68	Understanding human NK cell differentiation: Clues for improving the haploidentical hematopoietic stem cell transplantation. Immunology Letters, 2013, 155, 2-5.	2.5	5
69	NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on shortâ€term ILâ€2 activation. European Journal of Immunology, 2013, 43, 550-561.	2.9	41
70	Human NK cell receptors/markers: A tool to analyze NK cell development, subsets and function. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2013, 83A, 702-713.	1.5	175
71	Characterization of Human Afferent Lymph Dendritic Cells from Seroma Fluids. Journal of Immunology, 2013, 191, 4858-4866.	0.8	19
72	Polymorphism in Human Cytomegalovirus UL40 Impacts on Recognition of Human Leukocyte Antigen-E (HLA-E) by Natural Killer Cells. Journal of Biological Chemistry, 2013, 288, 8679-8690.	3.4	111

#	Article	IF	Citations
73	How melanoma cells inactivate NK cells. OncoImmunology, 2012, 1, 974-975.	4.6	26
74	Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity. Cancer Research, 2012, 72, 1407-1415.	0.9	267
75	Human NK cells at early stages of differentiation produce CXCL8 and express CD161 molecule that functions as an activating receptor. Blood, 2012, 119, 3987-3996.	1.4	69
76	Melanoma Cells Inhibit NK Cell Functionsâ€"Response. Cancer Research, 2012, 72, 5430-5430.	0.9	5
77	Melanoma immunoediting by NK cells. OncoImmunology, 2012, 1, 1607-1609.	4.6	15
78	Dendritic Cell Editing by Activated Natural Killer Cells Results in a More Protective Cancer-Specific Immune Response. PLoS ONE, 2012, 7, e39170.	2.5	95
79	Melanoma cells become resistant to <scp>NK</scp>â€cellâ€mediated killing when exposed to <scp>NK</scp>â€cell numbers compatible with <scp>NK</scp>â€cell infiltration in the tumor. European Journal of Immunology, 2012, 42, 1833-1842.	2.9	94
80	Killer Igâ€"like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood, 2011, 117, 764-771.	1.4	218
81	Origin, phenotype and function of human natural killer cells in pregnancy. Trends in Immunology, 2011, 32, 517-523.	6.8	138
82	Human NK receptors: From the molecules to the therapy of high risk leukemias. FEBS Letters, 2011, 585, 1563-1567.	2.8	36
83	CXCL12/CXCR4 Blockade Induces Multimodal Antitumor Effects That Prolong Survival in an Immunocompetent Mouse Model of Ovarian Cancer. Cancer Research, 2011, 71, 5522-5534.	0.9	206
84	CD34⁺hematopoietic precursors are present in human decidua and differentiate into natural killer cells upon interaction with stromal cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 2402-2407.	7.1	195
85	Seroma fluid subsequent to axillary lymph node dissection for breast cancer derives from an accumulation of afferent lymph. Immunology Letters, 2010, 131, 67-72.	2.5	35
86	The Immune Inhibitory Receptor LAIR-1 Is Highly Expressed by Plasmacytoid Dendritic Cells and Acts Complementary with NKp44 to Control IFNÎ± Production. PLoS ONE, 2010, 5, e15080.	2.5	64
87	Combined Genotypic and Phenotypic Killer Cell Ig-Like Receptor Analyses Reveal KIR2DL3 Alleles Displaying Unexpected Monoclonal Antibody Reactivity: Identification of the Amino Acid Residues Critical for Staining. Journal of Immunology, 2010, 185, 433-441.	0.8	32
88	The Emerging Role of HLA-E-Restricted CD8⁺T Lymphocytes in the Adaptive Immune Response to Pathogens and Tumors. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-8.	3.0	81
89	Crosstalk between decidual NK and CD14 ⁺ myelomonocytic cells results in induction of Tregs and immunosuppression. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 11918-11923.	7.1	220
90	CTLA-4 is expressed by human monocyteâ€"derived dendritic cells and regulates their functions. Human Immunology, 2010, 71, 934-941.	2.4	92

#	Article	IF	Citations
91	Immune response in the conjunctival epithelium of patients with dry eye. Experimental Eye Research, 2010, 91, 524-529.	2.6	66
92	Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20847-20852.	7.1	264
93	Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. International Immunology, 2009, 21, 793-801.	4.0	134
94	NKp44 expression, phylogenesis and function in non-human primate NK cells. International Immunology, 2009, 21, 245-255.	4.0	22
95	NK cells provide helper signal for CD8+ T cells by inducing the expression of membrane-bound IL-15 on DCs. International Immunology, 2009, 21, 599-606.	4.0	46
96	Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5. International Immunology, 2009, 21, 257-268.	4.0	25
97	Analysis of NK cell/DC interaction in NK-type lymphoproliferative disease of granular lymphocytes (LDGL): role of DNAM-1 and NKp30. Experimental Hematology, 2009, 37, 1167-1175.	0.4	15
98	Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: How NK cells make the difference. Clinical Immunology, 2009, 133, 171-178.	3.2	76
99	Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood, 2009, 113, 3119-3129.	1.4	343
100	HLA-E and HLA-E-Bound Peptides: Recognition by Subsets of NK and T Cells. Current Pharmaceutical Design, 2009, 15, 3336-3344.	1.9	45
101	Susceptibility of Human Melanoma Cells to Autologous Natural Killer (NK) Cell Killing: HLA-Related Effector Mechanisms and Role of Unlicensed NK Cells. PLoS ONE, 2009, 4, e8132.	2.5	36
102	Natural killer cells infiltrating human nonsmallâ€cell lung cancer are enriched in CD56^{bright}CD16^{â˜} cells and display an impaired capability to kill tumor cells. Cancer, 2008, 112, 863-875.	4.1	321
103	Perturbations of natural killer cell regulatory functions in respiratory allergic diseases. Journal of Allergy and Clinical Immunology, 2008, 121, 479-485.	2.9	58
104	Mesenchymal stem cells inhibit natural killerâ€“cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood, 2008, 111, 1327-1333.	1.4	998
105	Regulatory role of NKp44, NKp46, DNAM-1 and NKG2D receptors in the interaction between NK cells and trophoblast cells. Evidence for divergent functional profiles of decidual versus peripheral NK cells. International Immunology, 2008, 20, 1395-1405.	4.0	95
106	Methylprednisolone induces preferential and rapid differentiation of CD34+ cord blood precursors toward NK cells. International Immunology, 2008, 20, 565-575.	4.0	30
107	Generation of a Novel Regulatory NK Cell Subset from Peripheral Blood CD34+ Progenitors Promoted by Membrane-Bound IL-15. PLoS ONE, 2008, 3, e2241.	2.5	42
108	Differential NKp30 Inducibility in Chimpanzee NK Cells and Conserved NK Cell Phenotype and Function in Long-Term HIV-1-Infected Animals. Journal of Immunology, 2007, 178, 1702-1712.	0.8	28

#	Article	IF	Citations
109	Molecular analysis of the methylprednisolone-mediated inhibition of NK-cell function: evidence for different susceptibility of IL-2â€“ versus IL-15â€“activated NK cells. Blood, 2007, 109, 3767-3775.	1.4	73
110	Increased natural cytotoxicity receptor expression and relevant ILâ€10 production in NK cells from chronically infected viremic HCV patients. European Journal of Immunology, 2007, 37, 445-455.	2.9	192
111	Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood, 2006, 107, 1484-1490.	1.4	955
112	Surface NK receptors and their ligands on tumor cells. Seminars in Immunology, 2006, 18, 151-158.	5.6	247
113	Analysis of natural killer cells isolated from human decidua: evidence that 2B4 (CD244) functions as an inhibitory receptor and blocks NK-cell function. Blood, 2006, 108, 4078-4085.	1.4	117
114	Effector and regulatory events during natural killer?dendritic cell interactions. Immunological Reviews, 2006, 214, 219-228.	6.0	261
115	Analysis of the receptor-ligand interactions in the natural killerâ€mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood, 2005, 105, 2066-2073.	1.4	344
116	Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunology Letters, 2005, 100, 7-13.	2.5	113
117	Human cytolytic T lymphocytes expressing HLA class-I-specific inhibitory receptors. Current Opinion in Immunology, 2005, 17, 312-319.	5.5	29
118	Identification of effector-memory CMV-specific Tâ€„lymphocytes that kill CMV-infected target cells in an HLA-E-restricted fashion. European Journal of Immunology, 2005, 35, 3240-3247.	2.9	76
119	Distinctive Lack of CD48 Expression in Subsets of Human Dendritic Cells Tunes NK Cell Activation. Journal of Immunology, 2005, 175, 3690-3697.	0.8	26
120	Human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation: analysis of the surface expression and function of activating NK receptors. Molecular Immunology, 2005, 42, 405-411.	2.2	19
121	PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Molecular Immunology, 2005, 42, 463-469.	2.2	120
122	Analysis of the activating receptors and cytolytic function of human natural killer cells undergoingin vivo differentiation after allogeneic bone marrow transplantation. European Journal of Immunology, 2004, 34, 455-460.	2.9	48
123	Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1-infected patients. European Journal of Immunology, 2004, 34, 2313-2321.	2.9	121
124	The corticosteroid-induced inhibitory effect on NK cell function reflects down-regulation and/or dysfunction of triggering receptors involved in natural cytotoxicity. European Journal of Immunology, 2004, 34, 3028-3038.	2.9	83
125	Different checkpoints in human NK-cell activation. Trends in Immunology, 2004, 25, 670-676.	6.8	140
126	HLA-Eâ€restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes. Human Immunology, 2004, 65, 437-445.	2.4	42

#	Article	IF	Citations
127	Comparative analysis of NK- or NK-CTL-mediated lysis of immature or mature autologous dendritic cells. European Journal of Immunology, 2003, 33, 3427-3432.	2.9	16
128	Cellular and molecular basis of natural killer and natural killer-like activity. Immunology Letters, 2003, 88, 89-93.	2.5	25
129	Human natural killer cell function and their interactions with dendritic cells. Vaccine, 2003, 21, S38-S42.	3.8	41
130	NK-CTLs, a novel HLA-E-restricted T-cell subset. Trends in Immunology, 2003, 24, 136-143.	6.8	86
131	HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10896-10901.	7.1	175
132	Update on Natural Killer Cells. Cancer Journal (Sudbury, Mass), 2003, 9, 232-237.	2.0	3
133	Identification of HLA-E-specific alloreactive T lymphocytes: A cell subset that undergoes preferential expansion in mixed lymphocyte culture and displays a broad cytolytic activity against allogeneic cells. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11328-11333.	7.1	87
134	Human natural killer cells: their origin, receptors and function. European Journal of Immunology, 2002, 32, 1205.	2.9	217
135	Human NK cells and their receptors. Microbes and Infection, 2002, 4, 1539-1544.	1.9	64
136	What is a natural killer cell?. Nature Immunology, 2002, 3, 6-8.	14.5	312
137	Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis. Annual Review of Immunology, 2001, 19, 197-223.	21.8	1,609
138	p75/AIRM1 and CD33, two sialoadhesin receptors that regulate the proliferation or the survival of normal and leukemic myeloid cells. Immunological Reviews, 2001, 181, 260-268.	6.0	47
139	Regulation of myeloid cell proliferation and survival by p75/AIRM1 and CD33 surface receptors. Advances in Experimental Medicine and Biology, 2001, 495, 55-61.	1.6	4
140	Receptors involved in human NK cell activation in the process of natural cytotoxicity. , 2001, , 199-209.		0
141	Expression of HLA class I-specific inhibitory receptors in human cytolytic T lymphocytes: a regulated mechanism that controls T-cell activation and function. Human Immunology, 2000, 61, 44-50.	2.4	54
142	Distinct regulation of HLA class II and class I cell surface expression in the THP-1 macrophage cell line after bacterial phagocytosis. European Journal of Immunology, 1999, 29, 499-511.	2.9	22
143	Distinct regulation of HLA class II and class I cell surface expression in the THP-1 macrophage cell line after bacterial phagocytosis. European Journal of Immunology, 1999, 29, 499-511.	2.9	2
144	Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. Trends in Immunology, 1998, 19, 153-157.	7.5	230

#	Article	IF	Citations
145	Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunological Reviews, 1997, 155, 105-117.	6.0	333
146	Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor. European Journal of Immunology, 1997, 27, 1374-1380.	2.9	151
147	HLA-Class I-Specific Inhibitory Receptors of NK Type on a Subset of Human T Cells. Chemical Immunology and Allergy, 1996, 64, 135-145.	1.7	0
148	RECEPTORS FOR HLA CLASS-I MOLECULES IN HUMAN NATURAL KILLER CELLS. Annual Review of Immunology, 1996, 14, 619-648.	21.8	833
149	The molecular basis of Natural Killer (NK) cell recognition and function. Journal of Clinical Immunology, 1996, 16, 243-253.	3.8	35
150	Effect of superantigens on human thymocytes: selective proliferation of VÎ²2+ cells in response to toxic shock syndrome toxin-1 and their deletion upon secondary stimulation. International Immunology, 1996, 8, 203-209.	4.0	18
151	Role of major histocompatibility complex class I expression and natural killer-like T cells in the genetic control of endometriosis. Fertility and Sterility, 1995, 64, 909-916.	1.0	55
152	Cytolytic T lymphocytes displaying natural killer (NK)-like activity: expression of NK-related functional receptors for HLA class I molecules (p58 and CD94) and inhibitory effect on the TCR-mediated target cell lysis or lymphokine production. International Immunology, 1995, 7, 697-703.	4.0	216
153	T cell clones expressing the natural killer cell-related p58 receptor molecule display heterogeneity in phenotypic properties and p58 function. European Journal of Immunology, 1994, 24, 2294-2298.	2.9	134
154	Human Natural Killer Cells: Origin, Clonality, Specificity, and Receptors. Advances in Immunology, 1993, 55, 341-380.	2.2	197
155	Molecular and Cellular Analysis of Human T Lymphocytes Expressing gammadelta T-Cell Receptor. Immunological Reviews, 1991, 120, 117-135.	6.0	43
156	Specific recognition by CD3âˆ’ NK cells: A limiting dilution analysis of the frequency of alloreactive CD3âˆ’ lymphocyte precursors. International Journal of Cancer, 1989, 44, 56-57.	5.1	12
157	Surface Molecules Involved in the Activation and Regulation of T or Natural Killer Lymphocytes in Humans. Immunological Reviews, 1989, 111, 145-175.	6.0	67
158	Clonal analysis of CD4 CD8- human thymocytes expressing a T cell receptor Î³/Î´ chain. Direct evidence for the de novo expression of CD8 surface antigen and of cytolytic activity against tumor targets*. European Journal of Immunology, 1988, 18, 1831-1834.	2.9	38
159	Human CD3+4âˆ’8âˆ’WT31âˆ’T lymphocyte expressing the putative T cell receptor Î³-gene product. A limiting dilution and clonal analysis. European Journal of Immunology, 1987, 17, 1229-1234.	2.9	34
160	CD3+4âˆ’8âˆ’WT31âˆ’ (T cell receptor Î³+) cells and other unusual phenotypes are frequently detected among spontaneously interleukin 2-responsive T lymphocytes present in the joint fluid in juvenile rheumatoid arthritis. A clonal analysis. European Journal of Immunology, 1987, 17, 1815-1819.	2.9	81
161	T cell nature of some lymphokine-activated killer (LAK) cells. Frequency analysis of LAK precursors within human T cell populations and clonal analysis of LAK effector cells. European Journal of Immunology, 1986, 16, 1623-1625.	2.9	25
162	Assignment of human natural killer (NK)-like cells to the T cell lineage. Single allospecific T cell clones lyse specific or NK-sensitive target cells via distinct recognition structures. European Journal of Immunology, 1984, 14, 121-125.	2.9	55

#	Article	IF	Citations
163	Relationship between expression of FcÎ³ receptors or Ia antigens and cytolytic activities of alloactivated human T cells. Clinical Immunology and Immunopathology, 1983, 26, 232-239.	2.0	2
164	Surface markers of resting and activated human T cells. Functional implications and experimental limits. Seminars in Immunopathology, 1982, 5, 477-488.	4.0	5
165	9 Receptors for immunoglobulins and activation markers on human T lymphocytes. Clinics in Haematology, 1982, 11, 697-709.	2.3	4
166	Receptors for Immunoglobulins on Resting and Activated Human T Cells. Immunological Reviews, 1981, 56, 141-162.	6.0	52
167	Regulatory Interactions of Human T Cells. , 1980, , 275-288.		1
168	Human T Cell Subpopulations in Normal and Pathologic Conditions. Immunological Reviews, 1979, 45, 163-193.	6.0	104
169	Expression of a receptor for IgM by human T cellsin vitro. European Journal of Immunology, 1975, 5, 565-569.	2.9	441